209501orig1s000 - food and drug administration...guidance for industry: q3b(r2) impurities in new...
TRANSCRIPT
![Page 1: 209501Orig1s000 - Food and Drug Administration...Guidance for Industry: Q3B(R2) Impurities in New Drug Products es/ucm073389.pdf We note that all NDA applications filed after June](https://reader033.vdocuments.site/reader033/viewer/2022050311/5f734ee7281c5f312a622ce2/html5/thumbnails/1.jpg)
CENTER FOR DRUG EVALUATION AND RESEARCH
APPLICATION NUMBER:
209501Orig1s000
ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS
![Page 2: 209501Orig1s000 - Food and Drug Administration...Guidance for Industry: Q3B(R2) Impurities in New Drug Products es/ucm073389.pdf We note that all NDA applications filed after June](https://reader033.vdocuments.site/reader033/viewer/2022050311/5f734ee7281c5f312a622ce2/html5/thumbnails/2.jpg)
Reference ID: 4171138
![Page 3: 209501Orig1s000 - Food and Drug Administration...Guidance for Industry: Q3B(R2) Impurities in New Drug Products es/ucm073389.pdf We note that all NDA applications filed after June](https://reader033.vdocuments.site/reader033/viewer/2022050311/5f734ee7281c5f312a622ce2/html5/thumbnails/3.jpg)
Reference ID: 4171138
![Page 4: 209501Orig1s000 - Food and Drug Administration...Guidance for Industry: Q3B(R2) Impurities in New Drug Products es/ucm073389.pdf We note that all NDA applications filed after June](https://reader033.vdocuments.site/reader033/viewer/2022050311/5f734ee7281c5f312a622ce2/html5/thumbnails/4.jpg)
Reference ID: 4171138
![Page 5: 209501Orig1s000 - Food and Drug Administration...Guidance for Industry: Q3B(R2) Impurities in New Drug Products es/ucm073389.pdf We note that all NDA applications filed after June](https://reader033.vdocuments.site/reader033/viewer/2022050311/5f734ee7281c5f312a622ce2/html5/thumbnails/5.jpg)
![Page 6: 209501Orig1s000 - Food and Drug Administration...Guidance for Industry: Q3B(R2) Impurities in New Drug Products es/ucm073389.pdf We note that all NDA applications filed after June](https://reader033.vdocuments.site/reader033/viewer/2022050311/5f734ee7281c5f312a622ce2/html5/thumbnails/6.jpg)
![Page 7: 209501Orig1s000 - Food and Drug Administration...Guidance for Industry: Q3B(R2) Impurities in New Drug Products es/ucm073389.pdf We note that all NDA applications filed after June](https://reader033.vdocuments.site/reader033/viewer/2022050311/5f734ee7281c5f312a622ce2/html5/thumbnails/7.jpg)
![Page 8: 209501Orig1s000 - Food and Drug Administration...Guidance for Industry: Q3B(R2) Impurities in New Drug Products es/ucm073389.pdf We note that all NDA applications filed after June](https://reader033.vdocuments.site/reader033/viewer/2022050311/5f734ee7281c5f312a622ce2/html5/thumbnails/8.jpg)
![Page 9: 209501Orig1s000 - Food and Drug Administration...Guidance for Industry: Q3B(R2) Impurities in New Drug Products es/ucm073389.pdf We note that all NDA applications filed after June](https://reader033.vdocuments.site/reader033/viewer/2022050311/5f734ee7281c5f312a622ce2/html5/thumbnails/9.jpg)
Reference ID: 4171138
![Page 10: 209501Orig1s000 - Food and Drug Administration...Guidance for Industry: Q3B(R2) Impurities in New Drug Products es/ucm073389.pdf We note that all NDA applications filed after June](https://reader033.vdocuments.site/reader033/viewer/2022050311/5f734ee7281c5f312a622ce2/html5/thumbnails/10.jpg)
Reference ID: 4171138
![Page 11: 209501Orig1s000 - Food and Drug Administration...Guidance for Industry: Q3B(R2) Impurities in New Drug Products es/ucm073389.pdf We note that all NDA applications filed after June](https://reader033.vdocuments.site/reader033/viewer/2022050311/5f734ee7281c5f312a622ce2/html5/thumbnails/11.jpg)
![Page 12: 209501Orig1s000 - Food and Drug Administration...Guidance for Industry: Q3B(R2) Impurities in New Drug Products es/ucm073389.pdf We note that all NDA applications filed after June](https://reader033.vdocuments.site/reader033/viewer/2022050311/5f734ee7281c5f312a622ce2/html5/thumbnails/12.jpg)
![Page 13: 209501Orig1s000 - Food and Drug Administration...Guidance for Industry: Q3B(R2) Impurities in New Drug Products es/ucm073389.pdf We note that all NDA applications filed after June](https://reader033.vdocuments.site/reader033/viewer/2022050311/5f734ee7281c5f312a622ce2/html5/thumbnails/13.jpg)
![Page 14: 209501Orig1s000 - Food and Drug Administration...Guidance for Industry: Q3B(R2) Impurities in New Drug Products es/ucm073389.pdf We note that all NDA applications filed after June](https://reader033.vdocuments.site/reader033/viewer/2022050311/5f734ee7281c5f312a622ce2/html5/thumbnails/14.jpg)
Reference ID: 4171138
![Page 15: 209501Orig1s000 - Food and Drug Administration...Guidance for Industry: Q3B(R2) Impurities in New Drug Products es/ucm073389.pdf We note that all NDA applications filed after June](https://reader033.vdocuments.site/reader033/viewer/2022050311/5f734ee7281c5f312a622ce2/html5/thumbnails/15.jpg)
Reference ID: 4171138
![Page 16: 209501Orig1s000 - Food and Drug Administration...Guidance for Industry: Q3B(R2) Impurities in New Drug Products es/ucm073389.pdf We note that all NDA applications filed after June](https://reader033.vdocuments.site/reader033/viewer/2022050311/5f734ee7281c5f312a622ce2/html5/thumbnails/16.jpg)
Reference ID: 4171138
![Page 17: 209501Orig1s000 - Food and Drug Administration...Guidance for Industry: Q3B(R2) Impurities in New Drug Products es/ucm073389.pdf We note that all NDA applications filed after June](https://reader033.vdocuments.site/reader033/viewer/2022050311/5f734ee7281c5f312a622ce2/html5/thumbnails/17.jpg)
Reference ID: 4171138
![Page 18: 209501Orig1s000 - Food and Drug Administration...Guidance for Industry: Q3B(R2) Impurities in New Drug Products es/ucm073389.pdf We note that all NDA applications filed after June](https://reader033.vdocuments.site/reader033/viewer/2022050311/5f734ee7281c5f312a622ce2/html5/thumbnails/18.jpg)
Reference ID: 4171138
![Page 19: 209501Orig1s000 - Food and Drug Administration...Guidance for Industry: Q3B(R2) Impurities in New Drug Products es/ucm073389.pdf We note that all NDA applications filed after June](https://reader033.vdocuments.site/reader033/viewer/2022050311/5f734ee7281c5f312a622ce2/html5/thumbnails/19.jpg)
Reference ID: 4171138
![Page 20: 209501Orig1s000 - Food and Drug Administration...Guidance for Industry: Q3B(R2) Impurities in New Drug Products es/ucm073389.pdf We note that all NDA applications filed after June](https://reader033.vdocuments.site/reader033/viewer/2022050311/5f734ee7281c5f312a622ce2/html5/thumbnails/20.jpg)
![Page 21: 209501Orig1s000 - Food and Drug Administration...Guidance for Industry: Q3B(R2) Impurities in New Drug Products es/ucm073389.pdf We note that all NDA applications filed after June](https://reader033.vdocuments.site/reader033/viewer/2022050311/5f734ee7281c5f312a622ce2/html5/thumbnails/21.jpg)
Reference ID: 4171138
![Page 22: 209501Orig1s000 - Food and Drug Administration...Guidance for Industry: Q3B(R2) Impurities in New Drug Products es/ucm073389.pdf We note that all NDA applications filed after June](https://reader033.vdocuments.site/reader033/viewer/2022050311/5f734ee7281c5f312a622ce2/html5/thumbnails/22.jpg)
Reference ID: 4171138
![Page 23: 209501Orig1s000 - Food and Drug Administration...Guidance for Industry: Q3B(R2) Impurities in New Drug Products es/ucm073389.pdf We note that all NDA applications filed after June](https://reader033.vdocuments.site/reader033/viewer/2022050311/5f734ee7281c5f312a622ce2/html5/thumbnails/23.jpg)
![Page 24: 209501Orig1s000 - Food and Drug Administration...Guidance for Industry: Q3B(R2) Impurities in New Drug Products es/ucm073389.pdf We note that all NDA applications filed after June](https://reader033.vdocuments.site/reader033/viewer/2022050311/5f734ee7281c5f312a622ce2/html5/thumbnails/24.jpg)
![Page 25: 209501Orig1s000 - Food and Drug Administration...Guidance for Industry: Q3B(R2) Impurities in New Drug Products es/ucm073389.pdf We note that all NDA applications filed after June](https://reader033.vdocuments.site/reader033/viewer/2022050311/5f734ee7281c5f312a622ce2/html5/thumbnails/25.jpg)
Reference ID: 4171138